You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201421 - 201430 of 204654 results
  1. ENZYMATIC SYNTHESIS OF GLYCANS

    SBC: CASSIA, LLC            Topic: NCI

    This proposal outlines a plan to synthesize standard samples of a range of glycans as reference compounds in glycomics research. Cassia, LLC shall work in collaboration with the Paulson laboratory at The Scripps Research Institute to make these compoundscommercially available to the research community. The Specific Aims include enzymatic synthesis of 20-32 glycans as either terminal fragments, ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. TOPIC 319 PHASE I; TECHNOLOGY TO GENERATE ANTI PEPTICE CAPTURE REAGENS AFFINITY E

    SBC: BASE PAIR BIOTECHNOLOGIES INC            Topic: NCI

    The stated Phase I activities and expected deliverables of this SBIR Contract include: 1) Development of proof-of-concept technologies that reliably generate anti-peptide capture reagents that can immunoprecipitate the target peptides; 2) Demonstrate that the capture reagents developed can reproducibly immunoprecipitate the target peptides; 3) Work with the CPTC community, private and public se ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. The contractor will develop COMPASS, a device-agnostic platform that measures and

    SBC: EveryFit, Inc. (DBA "QMedic")            Topic: NCI

    This proposal was submitted under the SBIR Fast-track process. In Phase I, the primary purpose is to develop COMPASS; a device-agnostic platform that measures and delivers customizable, evidence-informed rehabilitation services to cancer survivors/patientsusing mobile phones/tablets, objective measurement sensors (such as accelerometers, gyroscopes, electro-dermal response for affect, indoor locat ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. TOPIC 322 PHASE 1; REAL TIME INTEGRATION OF SENSOR AND SELF REPORT DATA FOR CLINI

    SBC: Vignet Inc.            Topic: NCI

    This proposal was submitted under the SBIR Fast-track process. In Phase I, the primary purpose is to develop a sensor-enhanced health information system for many different health contexts including prevention and management of chronic diseases such as cancers. In Phase II, Vignet will combine several innovative technologies and methods into a comprehensive, integrated, end-to-end sensor-enhanced d ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. The proposed research uses mobile and digital technology to provide real-time dat

    SBC: ZANSORS LLC            Topic: NCI

    The primary purpose is to develop a real-time method of monitoring lymphedema patients symptoms to be used with a smartphone or tablet when the patients are away from their clinic. The Offeror has set three substantial objectives for this prototype platform (see below). The technologies will be developed using both open-source and proprietary components and will provide an innovative way to colle ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. TOPIC 324 PHASE I 9 MONTH FUNDING; NOVEL IMAGING AGENTS T EXPAND TE CLINICAL TOOL

    SBC: ROCKLAND IMMUNOCHEMICALS, INC.            Topic: NCI

    Medical imaging and targeted therapy are the central components in the clinical management of cancer patients. Rockland Immunochemicals, Inc. is teaming up with Abzyme Therapeutics LLC to develop novel imaging agents that can be used in both cancer diagnosis and targeted therapy. In this phase I proposal, high-affinity camelid single domain antibodies to three cancer biomarkers HER2, EGFR and meso ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Contract Title: SBIR Phase I Topic 324 Development of an Imaging Agent Targeting

    SBC: MABVAX THERAPEUTICS, INC.            Topic: NCI

    The carbohydrate antigen sialyl-Lewis a (sLea), also known as CA19.9, is widely expressed in pancreatic cancer (PC), and serum CA19.9 expression is used as a tumor marker in PC. sLea serves as a ligand for E-selectin adhesion molecules and over-expressionof sLea may be a key event in invasion and metastasis. We have generated a series of fully human monoclonal antibodies (mAb) and 5B1 (IgG1/and#95 ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. SBIR Topic 314- High Content Screening of 3D Cultured Cancer Cells

    SBC: BioTime, Inc.            Topic: NCI

    Not Available

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. IGF::OT::IGF Compact, Low-Cost, High-Intensity Superconducting Isochronous Cyclot

    SBC: T Antaya, LLC            Topic: NCI

    Not Available

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. TOPIC 324 PHASE I; NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL TOOL KIT FOR CANCE

    SBC: EVORX TECHNOLOGIES, INC.            Topic: NCI

    Targeted molecular imaging of cancer is vital for better personalized medicine, but requires novel imaging agents that recognize key molecular surface cell markers. Her2 is overexpressed in 20-30% of breast cancer and is targeted by Herceptin, yet no molecular imaging agent for Her2 is clinically approved. We propose to use Scanning Unnatural Protease Resistant (SUPR) peptides to develop a novel H ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government